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OBJECTIVE—Increased deposition of extracellular matrix
(ECM) within the kidney is driven by proﬁbrotic mediators
including transforming growth factor- (TGF-) and connective
tissue growth factor (CTGF). We investigated whether some of
their effects may be mediated through changes in expression of
certain microRNAs (miRNAs).
RESEARCH DESIGN AND METHODS—Proximal tubular
cells, primary rat mesangial cells, and human podocytes were
analyzed for changes in the expression of key genes, ECM
proteins, and miRNA after exposure to TGF- (1–10 ng/l).
Tubular cells were also infected with CTGF-adenovirus. Kidneys
from diabetic apoE mice were also analyzed for changes in gene
expression and miRNA levels.
RESULTS—TGF- treatment was associated with morphologic
and phenotypic changes typical of epithelial-mesenchymal tran-
sition (EMT) including increased ﬁbrogenesis in all renal cell types
and decreased E-cadherin expression in tubular cells. TGF- treat-
ment also modulated the expression of certain miRNAs, including
decreased expression of miR-192/215 in tubular cells, mesangial
cells, which are also decreased in diabetic kidney. Ectopic
expression of miR-192/215 increased E-cadherin levels via re-
pressed translation of ZEB2 mRNA, in the presence and absence
of TGF-, as demonstrated by a ZEB2 3-untranslated region
luciferase reporter assay. However, ectopic expression of miR-
192/215 did not affect the expression of matrix proteins or their
induction by TGF-. In contrast, CTGF increased miR-192/215
levels, causing a decrease in ZEB2, and consequently increased
E-cadherin mRNA.
CONCLUSIONS—These data demonstrate the linking role of
miRNA-192/215 and ZEB2 in TGF-/CTGF–mediated changes in
E-cadherin expression. These changes appear to occur indepen-
dently of augmentation of matrix protein synthesis, suggesting
that a multistep EMT program is not necessary for ﬁbrogenesis to
occur. Diabetes 59:1794–1802, 2010
D
iabetic nephropathy is a major microvascular
complication and a leading cause of chronic
kidney failure in individuals with both type 1
and type 2 diabetes. The risk is dramatically
elevated with poor blood glucose control and the greatest
rate of progression occurs with elevated blood pressure,
conﬁrming that hemodynamic and metabolic factors par-
ticipate in the development and progression of this disor-
der. The glomerulus is considered to be the primary site of
initial renal injury, but increasing evidence points to the
tubulointerstitium also playing a critical role via the pro-
cess of epithelial-mesenchymal transition (EMT) (1). Dur-
ing this process, epithelial cells acquire features of
mesenchymal cells such as myoﬁbroblasts, resulting in
loss of E-cadherin expression, the acquisition of mesen-
chymal markers such as -smooth muscle actin (-SMA),
and the increased deposition of extracellular matrix
(ECM).
In vivo evidence for EMT in diabetic kidney has been
controversial. A partial EMT (p-EMT) phenotype was
recently described (2,3), identifying cells expressing both
epithelial and mesenchymal markers. This phenotype is
relevant because the acquisition of mesenchymal markers
and expression of ECM proteins that occur early in EMT
may be transient, occurring in cells exposed to the dia-
betic milieu and contributing to ﬁbrosis. We previously
demonstrated that connective tissue growth factor (CTGF)
induces the p-EMT phenotype in proximal tubular cells
that express -SMA and ECM proteins while maintaining
the expression of the epithelial marker, E-cadherin (4).
The mechanisms underlying the partial EMT phenotype
and the reasons that E-cadherin is spared in this situation
have not been clear.
Several proﬁbrotic factors and pathways are known to
drive EMT (2,5), primarily by converging on the Snail and
ZEB families of transcriptional repressors of E-cadherin
that bind to the E-cadherin promoter (6–9) and collagen
expression (10). These factors play a role in maintaining
the mesenchymal phenotype (11). Recent reports have
established a role for microRNAs (miRNAs) in the process
of EMT by regulating the expression of ZEB2. The miR-200
family regulates transforming growth factor (TGF)-–
mediated EMT in MDCK cells via targeting of ZEB1/2 (7).
Interestingly, ZEB1/2 were found to be negative transcrip-
tional regulators of the miR-200 family (7). This observa-
tion has been conﬁrmed by others (12–15) and for the ﬁrst
time demonstrates clear cross-talk between miRNA
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role for miRNAs in EMT and ﬁbrosis.
Recently, several miRNAs (miR-192, -194, -215, and -216)
were identiﬁed as preferentially and highly expressed in
kidney (16). One of these, miR-192, was increased by
TGF- treatment in mesangial cells and in the kidney in
experimental diabetes and was associated with increased
expression of col1a2 (10). Also, miR-192 and miR-215 were
recently demonstrated to play a role in cell cycle control
(17,18). In more recent studies, miR-192 was increased in
human kidney in both hypertensive nephrosclerosis (19)
and IgA nephropathy but not in glomerulosclerosis (20). In
those studies, miR-192 levels did not correlate with mark-
ers of EMT or ﬁbrosis, whereas members of the miR-200
family did. The role of miR-192 in human kidney disease
therefore appears to be more complex than originally
reported.
In this study we investigated the role of the miR-192/215
family as translational regulators of the ZEB2 transcription
factor and ECM production in a number of renal cells,
including proximal tubular cells, primary mesangial cells,
and human conditionally immortalized podocytes. In ad-
dition, we examined these miRNAs in the kidney of
streptozotocin (STZ)-induced diabetic apoE
/ mice,
which is a model of more advanced renal disease with
prominent ﬁbrosis and EMT. We have demonstrated that
the miR-192/215 family is indeed a regulator of E-cadherin
expression but not ECM.
RESEARCH DESIGN AND METHODS
Cell culture. The rat kidney tubular epithelial cell line (NRK-52E) was
obtained from the American Type Culture Collection (Rockville, MD) and
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (4). Primary
mesangial cells were isolated and cultured as previously described (21,22).
Human conditionally immortalized podocytes were propagated as previously
described (23). Experimental treatments for all cell lines were in serum-
reduced conditions (2%) with recombinant human TGF- (R&D Systems,
Minneapolis, MN).
RNA extraction and real-time PCR. Gene expression analysis was by
real-time RT-PCR (24) using the TaqMan system based on real-time detection
of accumulated ﬂuorescence (ABI Prism 7500; Perkin-Elmer). Gene expres-
sion levels were normalized against 18S rRNA (18S rRNA TaqMan Control
Reagent Kit, ABI Prism 7500; Perkin-Elmer). Details of primers and TaqMan
probes for most genes have been previously reported (4). Triplicate experi-
ments were performed, with six replicates. Results are expressed relative to
control, which was arbitrarily assigned a value of 1. Values are shown as
means  SEM unless otherwise speciﬁed. P  0.05 was considered signiﬁcant
(Student t test).
miRNA assays. For miRNA analysis, cDNA synthesis and real-time PCR were
performed using TaqMan miRNA assays per the manufacturer’s recommen-
dations (Applied Biosystems, Foster City, CA). Experimental groups were in
replicates of six and normalized to RN6UB, Sno135, or U87 for rat, human, and
mouse samples, respectively. Values are shown as means  SEM unless
otherwise speciﬁed. P  0.05 was considered signiﬁcant (t test).
Transfection of miRNA Precursors and Inhibitors. NRK52E cells were
seeded at 3  10
4 cells per well in 12-well plates and transfected the following
day in OptiMEM medium (Invitrogen) with premiRNAs (100 nmol/l) or
anti-miRNA (100–200 nm) (Applied Biosystems) using Oligofectamine (In-
vitrogen). Cells were harvested 3 days after transfection.
Western analysis. Precast gels (4–12%) were used for ZEB2 analyses. ZEB2
antibody was obtained from Santa Cruz. Quantitation of blots was carried out
using Quantity One software on the Chemidoc XRS imaging system (Bio-Rad).
Snail and ZEB2 3untranslated region-luciferase reporter analyses.
The luciferase-3 untranslated region (UTR) ZEB2 construct contains the
conserved region among human, mouse, and rat ZEB2 genes (7). NRK52E cells
were cotransfected with RL-reporter plasmids (0.5 g/ml), cytomegalovirus-
galactosidase construct, and miRNA or miRNA inhibitors, using Lipo-
fectamine 2000 (Invitrogen) in OptiMEM medium (Invitrogen). Cells were
harvested 48 h after transfection using the Luciferase Reporter Assay System
(Promega), and luciferase and galactosidase assays were performed per the
manufacturer’s recommendations. All experiments were repeated at least
twice and performed in triplicate. Values are shown as means  SEM unless
otherwise speciﬁed. P  0.05 was considered signiﬁcant.
Immunoﬂuorescence. Cells were grown on coverslips, washed twice with
PBS, ﬁxed in 4% paraformaldehyde for 20 min, permeabilized using 1% SDS,
and incubated in a blocking buffer (1% BSA, 0.25% Triton X-100 in PBS, pH
7.4). Primary and secondary antibodies were diluted in blocking buffer and
incubated with cells overnight at room temperature. Coverslips were then
mounted using Prolog Gold antifade reagent with DAPI (Invitrogen), and cells
were viewed using an Olympus BX61 ﬂuorescence microscope. Primary
antibodies were -SMA (clone 1A4; Dako, Cupertino, CA), E-cadherin (Trans-
duction Laboratories, Lexington, KY), ZO-1 (Invitrogen), vimentin (Sigma, St.
Louis, MO), ﬁbronectin (Sigma), and nephrin (Santa Cruz). Secondary anti-
bodies included Alexa Fluor 488 (mouse anti-rabbit and goat anti-rabbit) and
Alexa Fluor 594 (rabbit anti-goat). F-actin was stained with phalloidin (red)
(Invitrogen).
In vivo studies. To explore the relationship between miR-192/215 and the
development of ﬁbrotic kidney disease, a study was carried out using apoE
knockout mice (n 	 8/group) that were rendered diabetic by ﬁve daily
intraperitoneal STZ injections as previously described (25). Only animals with
blood glucose levels 
15 mmol/l at 5 days after the induction of diabetes
(
90% of injected mice) were included in the study. After 10 weeks, animals
were anesthetized and killed, and tissues were collected as previously
described (25).
Immunohistochemistry. Four-micrometer parafﬁn kidney sections were
used for immunohistochemical analyses as previously described (25,26).
Primary antibodies were -SMA (clone 1A4; Dako), collagen IV (Southern
Biotechnology, Birmingham, AL), and ﬁbronectin (Dako) and used as previ-
ously described (25,26). Finally, sections were counterstained with Mayer’s
hematoxylin, dehydrated, and mounted and analyzed for staining using light
microscopy (Olympus BX-50; Olympus Optical, Tokyo, Japan).
RESULTS
TGF- induces expression of ECM proteins and
markers of EMT in renal cells. TGF- is a powerful
inducer of ECM protein expression and ﬁbrosis in many
cell types, as well as an inducer of EMT in epithelial cells.
To determine the effect of TGF- on the kidney-speciﬁc
miRNAs (16) and correlate the observed changes with
expression of ECM proteins, three renal cell types were
studied. These included proximal tubular cells, primary
mesangial cells, and human conditionally immortalized
podocytes, representing the main kidney cell types poten-
tially contributing to the development of ﬁbrosis in the
diabetic kidney.
TGF- induced the classic EMT morphologic changes in
NRK52E cells, including the elongation of cells with a loss
of apical-basal polarity (Fig. 1A) as previously reported
(4). These changes were associated with decreased ex-
pression of the epithelial marker ZO-1 and increased
staining for F-actin, vimentin, and ﬁbronectin (Fig. 1A).
Signiﬁcant increases were observed in the mRNA levels of
-SMA, vimentin, ﬁbronectin, CTGF, and collagens I and
IV, with a decrease of the epithelial marker, E-cadherin
(Fig. 1B). Interestingly, the transcriptional repressors of
E-cadherin, SNAI1, and ZEB2, were increased twofold
(Fig. 1B). In this particular model of EMT, TGF- had
minimal effect on cell proliferation as evidenced by the
marginal decrease in PCNA expression (supplementary
Fig. 2, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1736/DC1).
TGF- also induced morphologic changes in primary
rat mesangial cells (Fig. 1C), with increased expression
of SMA, vimentin, and ﬁbronectin, compared with
control cells. Signiﬁcant increases in vimentin, ﬁbronec-
tin, collagens I and IV, CTGF, SNAI1, and ZEB1 mRNA
were observed (Fig. 1D). Interestingly, despite a modest
increase in -SMA protein (Fig. 1C), TGF- caused a
decrease in -SMA mRNA (Fig. 1D), suggesting that the
regulation of SMA protein expression is more complex
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FIG. 1. TGF- induced changes in renal cell morphology, protein, and gene expression. A: NRK52E cells (DMEM, 25 mmol/l glucose, 2% serum), were
treated with TGF- (10 ng/ml, 3 days). Light microscopy (Light M.) images (20) demonstrate that TGF- causes a loss of the typical epithelial
morphology to larger and more irregularly-shaped cells typical of the myoﬁbroblast phenotype. TGF- treatment also caused a dramatic decrease of
ZO-1 expression at tight junctions between neighboring cells (green) accompanied with increased F-actin expression (red) (40). Nuclei were stained
with DAPI. Expression of vimentin and ﬁbronectin protein was also dramatically increased with TGF- treatment (green). B: The expression of several
genes was assessed by real-time quantitative PCR in NRK52E cells and the signiﬁcant changes caused by TGF- treatment are indicated (*P < 0.05,
compared with control). C: Rat mesangial cells (DMEM, 2% serum) were treated with TGF- (10 ng/ml, 3 days). Changes in morphology are evident by
light microscopy (20) with cells adopting a more spindly appearance after TGFtreatment. Immunostaining for -SMA expression was increased with
TGF-, as were vimentin and ﬁbronectin (green). A change in F-actin arrangement (red) was more obvious after TGF- treatment. D: The expression
of a number of genes was assessed by real-time quantitative PCR and signiﬁcant changes in response to TGF- are indicated (*P < 0.05, compared with
control). E: Human podocytes were seeded (33°C) and subsequently differentiated (37.8°C, 10–14 days), followed by treatment with TGF- (10 ng/ml,
3 days, RPMI with 2% serum). Light microscopy (20) reveals a dramatic change in phenotype with loss of the typical arborized morphology in control
cells, becoming hypertrophic, elongated, and in close proximity with neighboring cells after TGF- treatment. Immunostaining of podocytes revealed
increased -SMA (green) with TGF- treatment. Vimentin staining (green) was also increased and altered with rearrangement from ﬁne ﬁbers
radiating from the nucleus to the periphery to very strong staining and thicker ﬁbers with TGF-. Fibronectin was also signiﬁcantly increased (green)
from being mainly associated with the nucleus to a more patchy cytoplasmic localization after treatment with TGF-. All error bars represent  SEM.
F: Gene expression analysis by real-time quantitative PCR revealed signiﬁcant changes after treatment with TGF- as indicated (*P < 0.05, compared
with control). G: Mature and differentiated podocytes were characterized by punctuated nephrin expression (red) at the periphery of untreated cells
as distinct spots, conﬁrming the identity of these cells as podocytes (enlarged inset).
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cells.
The effect of TGF- on human conditionally immor-
talized podocytes was also investigated. Upon differen-
tiation, these cells expressed the podocyte-speciﬁc slit-
pore protein, nephrin, which was punctuated and
present at the cell periphery (Fig. 1G) as previously
described (23). Podocyte morphology was also dramat-
ically altered in TGF-–treated cells with cells losing
their arborized irregular ﬂat shape and becoming more
dense and elongated (Fig. 1E). Increased staining for
-SMA, vimentin, and ﬁbronectin was also observed
after treatment with TGF- with the appearance and
organization altered by TGF- in each case (Fig. 1E).
TGF- treatment signiﬁcantly increased -SMA, vimen-
tin, CTGF, collagen IV, and SNAI1 RNA (Fig. 1F). In
contrast, levels of SNAI2 and ZEB2 were signiﬁcantly
decreased and ZEB1 remained unchanged. These results
are consistent with the recently described changes
described in murine podocytes after TGF- treatment
(27) leading to podocyte dysfunction.
From these experiments, it was evident that all three
renal cell types increased expression of ECM proteins in
response to TGF-, conﬁrming that each cell type may
potentially contribute to the deposition of ECM and,
hence, ﬁbrosis in diabetic nephropathy. The underlying
mechanism is likely to involve part of the EMT program
in epithelial cells such as proximal tubular cells, but
also occurs in the absence of EMT in mesangial cells
and podocytes. Changes in the mRNA levels of the
transcriptional repressors of E-cadherin, SNAI1/2, and
ZEB1/2, which have been previously implicated in EMT
in epithelial cells, were also observed in proximal
tubular cells; however, these changes did not appear to
be consistent with ECM production in the other cell
types.
TGF- alters the expression of “kidney-speciﬁc”
miRNAs. Given that a number of miRNAs (miRNA-192,
-194, -204, -215, and -216) are highly expressed in kidney
tissue (16), we examined whether TGF- could alter their
expression in proximal tubular cells. Analysis of miRNA
levels in NRK52E cells adapted to TGF- identiﬁed signif-
icant decreases in miR-192, -194, and -215 (68, 74, and
46%, respectively) compared with control cells (Fig. 2A).
We also observed that miR-204 was signiﬁcantly increased
(54%) and miR-216 remained unchanged. Interestingly,
both miR-192 and miR-215, which belong to the same
family and share the same seed sequence (Fig. 3A), were
both downregulated by TGF-. These observations dem-
onstrate that the expression of certain miRNAs is altered
in tubular cells in response to TGF-, consistent with the
possibility that miRNAs may mediate some of the proﬁ-
brotic effects of TGF- in the kidney.
miR-192/215 expression in renal cells is downregu-
lated by TGF-. Our ﬁnding that both miR-192 and
miR-215 were decreased in proximal tubular cells by
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FIG. 2. Changes in kidney-speciﬁc miRNAs in renal cells after TGF- treatment, as well as miRNA and gene expression changes in diabetic mouse
kidney. A: NRK52E cells were cultured in the presence of TGF- (10 ng/ml, 10 days) before miRNA expression levels were assessed by real-time
quantitative PCR. A signiﬁcant increase was observed in miR-204, whereas miR-192, miR-194, and miR-215 were signiﬁcantly decreased (*P <
0.05, compared with control). B: The experiment was repeated with a shorter exposure to TGF- (10 ng/ml, 3 days), and levels of miR-192 and
miR-215 were assessed in proximal tubular cells (NRK52E), primary rat mesangial cells, and human podocytes. Both miRNAs were signiﬁcantly
decreased with TGF- in proximal tubular and mesangial cells (*P < 0.05, compared with control). C: TGF- (10 ng/ml, 3 days) also decreased
the expression of some members of the miR-200 family in NRK52E cells (* P < 0.05, compared with control), whereas expression of miR-16
remained unaltered. D: RNA extracted from the renal cortex of control and 10-week diabetic apoE mice (n  10 per group) displayed a signiﬁcant
decrease for both miR-192 and miR-215 in diabetic mice (*P < 0.05, compared with control). E: Gene expression analysis of control and 10-week
diabetic kidney was assessed by real-time quantitative PCR for a number of genes. Signiﬁcant increases were observed in -SMA, ﬁbronectin,
collagen 4, CTGF, TGF-, and ZEB2 (*P < 0.05, compared with control). F: Immunohistochemical analysis demonstrates increased staining for
-SMA, collagen IV, and ﬁbronectin in the kidneys of 10-week diabetic apoE knockout mice compared with control. All error bars represent 
SEM.
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was increased in mouse mesangial cells and correlated
with increased col1a2. In that work, serum starvation
caused a signiﬁcant decrease in miR-192 and TGF- treat-
ment and restored expression to that observed in cells
grown in the presence of serum. In the same study, TGF-
decreased miR-215, which was consistent with our obser-
vations. We therefore examined miR-192/215 levels after a
short exposure (3 days) to TGF- and observed signiﬁ-
cantly decreased miR-192/215 levels in NRK52E cells and
mesangial cells (Fig. 2B). Human podocytes displayed the
same trend; however, the differences did not reach signif-
icance. The importance of these miRNAs to the TGF-
response of podocytes remains to be determined. These
data demonstrate that the three renal cell populations
studied all respond to TGF- by increasing expression of
ECM proteins, but also by reducing the expression of
miR-192/215, suggesting that these miRNA changes may
possibly contribute to ﬁbrotic changes in the diabetic
kidney. In all cell types, miR-192 was more abundantly
expressed than miR-215 (supplementary Fig. 1, available in
an online appendix). We also assessed the expression of
some members of the miR-200 family as these have been
previously shown to be downregulated with TGF- in
other cell lines and are drivers of the EMT phenotype in
epithelial cells (7). As shown in Fig. 2C, miR-200a, -200b,
and -200c were all signiﬁcantly decreased with TGF- in
NRK52E cells, consistent with the earlier reports. How-
ever, miR-16 is considered to be relatively inert and did not
alter with TGF- treatment.
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activity (P < 0.05 compared with control). MiR-192/215 signiﬁcantly reduced luciferase activity from the ZEB2 3UTR in the absence (*P < 0.05)
or presence (#P < 0.001) of TGF-, compared with control. C: Anti-miR-192/215 (anti-miRs) had no effect on the luciferase activity of the ZEB2
3UTR construct compared with control. D: Western analysis and quantitation for ZEB2 expression in NRK52E cells transfected as in B with
miR-control and miR-192/215. miR-192/215 signiﬁcantly reduced ZEB2 protein expression (*P < 0.05, compared with control). E: Western
analyses and quantitation of ZEB2 expression in NRK52E cells transfected either with miR-conrtol or miR-192/215 in the presence or absence of
TGF. miR-control had no effect on the increased expression of ZEB2 induced by TGF-; however, miR-192/215 prevented this induction (*P <
0.05, compared with control). All error bars represent  SEM.
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out diabetic mouse kidney. Changes in miRNA levels in
in vitro models are well documented. To determine the
relationship between miR-192/215 and diabetic kidney
disease, we examined kidney cortex from STZ-induced
diabetic apoE knockout mice. As observed in our in vitro
experiments, miR-192/215 were signiﬁcantly decreased
(40 and 43%, respectively) in diabetic kidney compared
with control (Fig. 2D). These data are in contrast to the
work of Kato et al. (10) who reported an increase in
miR-192, albeit in different models, the STZ-induced dia-
betic C57BL/6 mouse kidney (7-week) and in the kidneys
of 10-week db/db mice, but more consistent with human
glomerulosclerosis and diabetes (20,28). The decrease in
miR-192/215 was associated with increased ZEB2 RNA
(Fig. 2E) and protein (see later Fig. 3D), consistent with
our observations in NRK52E cells. Levels of -SMA, ﬁ-
bronectin, CTGF, collagen IV, and TGF- mRNA were
signiﬁcantly increased in diabetic kidney (Fig. 2E), as were
protein levels of SMA, collagen IV, and ﬁbronectin (Fig.
2F). These in vivo observations are consistent with the in
vitro data and suggest that decreased levels of miR-192/215
are associated with enhanced renal ﬁbrosis in diabetes.
These ﬁndings are consistent with the progression of renal
ﬁbrosis, occurring at least in part via a mechanism that
involves dysregulation of ZEB2 and, consequently,
E-cadherin.
miR-192 and miR-215 target the ZEB2 3UTR. miR-192
and miR-215 share the same seed sequence (Fig. 3A) and
are expressed in renal cells (Fig. 2B). The ZEB2 3UTR
contains several sites for the miR-200 family (7), including
a single site for miR-192/215 (Fig. 3A). Because ZEB2
mRNA (Fig. 1B) and protein (Fig. 3E) are increased by
TGF- in NRK52E cells, we investigated whether these
genes might be targeted by miR-192/215 for translational
repression. NRK52E cells cotransfected with the ZEB2
3UTR-luciferase reporter construct and the miR-control
had signiﬁcantly increased luciferase activity after TGF-
treatment (78%; Fig. 3B). In the same experiment, miR-
192 and miR-215 totally abolished the TGF-–induced
increase in luciferase activity (90 and 88%, respectively),
even lower than that observed in non-TGF-–treated cells
(Fig. 3B). The above data conﬁrm that both miR-192 and
miR-215 independently act as speciﬁc and potent transla-
tional repressors of ZEB2 by targeting the 3UTR of this
gene. This is in contrast with the earlier report in which
miR-215 was not shown to have any effect on ZEB2 (10). In
similar experiments we tested whether the translational
repression of the ZEB2 3UTR by endogenous miR-192/215
could be relieved by anti-miR-192/215, however no in-
crease in luciferase activity was observed (Fig. 3C). This
was not surprising since a plethora of miRNAs target the
3UTR of ZEB2, including the members of the miR-200
family (Fig. 2C) which bind at several sites (7). In the
absence of TGF-, all of these miRNAs would have to be
inhibited to relieve translational repression acting on the
3UTR of ZEB2.
Western analysis of NRK52E cells transfected with
miR-192/215 revealed a small but signiﬁcant reduction in
ZEB2 protein levels (27%, P  0.05; Fig. 3D) compared
with control. This is consistent with ZEB2 expression
being tightly regulated in resting cells. TGF- treatment
resulted in a signiﬁcant increase of ZEB2 protein in
miR-control–transfected cells compared with the control
(36%, P  0.05; Fig. 3E, left panels). This TGF--induced
increase in ZEB2 protein, however, was abrogated when
cells were transfected with miR-192/215 (Fig. 3E, right
panels), conﬁrming our 3UTR data (Fig. 3B) that miR-192/
215 regulate ZEB2 translation and, therefore, protein
levels.
Although the direct targeting of the ZEB2 3UTR by
miR-192/215 for translational repression is clear, the mech-
anism behind the observed TGF-–induced changes in
ZEB2 mRNA in the different renal cells is more complex
(Fig. 1). This may relate in part to the feedback loop
between the miR-200 family and the translation/transcrip-
tion of ZEB1/2 in some TGF-–treated cells (29), as well as
the ability of miRNAs to alter the stability of their target
mRNAs as recently described by Hendrickson et al. (30).
miR-192/215 regulate the transcription of E-cadherin
but not ECM proteins. ZEB2 is a well-known regulator
of E-cadherin transcription. Based on the above observa-
tions, we hypothesized that the miR-192/215 family regu-
lated E-cadherin expression through ZEB2 and possibly
ECM accumulation via modulation of the EMT phenotype.
Downregulation of mir-192/215 may be a contributing
factor to how TGF- drives EMT and the development of
renal ﬁbrosis. To test this hypothesis, NRK52E cells were
transfected with miR-192, miR-215, or miR-control in the
absence of TGF-. Expression analysis demonstrated that
miR-192 and miR-215 independently elevated E-cadherin
mRNA levels compared with miR-control; however, only
the miR-215-mediated increase was signiﬁcant (76%, P 
0.05; Fig. 4A). We performed a separate experiment in
TGF-–adapted NRK52E cells, which typically have re-
duced E-cadherin (Fig. 1B) and found that E-cadherin
mRNA levels were signiﬁcantly increased (Fig. 4B) by both
miR-192 and miR-215 (85 and 75%, respectively, P 
0.05) compared with miR-control–transfected cells. Inter-
estingly, the expression of -SMA, ﬁbronectin, vimentin,
and collagen I and IV was not altered with miR-192/215 in
the absence (Fig. 4C) or presence of TGF- (Fig. 4D).
These experiments demonstrate that although miR-192/
215 alter the expression of E-cadherin via ZEB2, they do
not directly alter ECM protein expression in proximal
tubular cells.
We further wished to establish whether ectopic expres-
sion of miR-192/215 could prevent the TGF-–induced
downregulation of E-cadherin. NRK52E cells transfected
with miR-control had signiﬁcantly decreased E-cadherin
levels after TGF- treatment (P  0.001; Fig. 4E), which
was partially but signiﬁcantly reversed by both miR-192
(1.7-fold) and miR-215 (2.1-fold) (P  0.05; Fig. 4E).
Total reversal may not be possible as several TGF-–
responsive factors may act to regulate E-cadherin levels
apart from miR-192/215. These data conﬁrm that miR-192/
215 can partially reverse the downregulation of E-cadherin
by TGF- in proximal tubular cells and potentially play a
role in regulating the epithelial cell phenotype.
CTGF results in increased levels of miR-192/215 and
increased E-cadherin mRNA. We previously demon-
strated that CTGF causes NRK52E cells to undergo partial
EMT (4) independently of TGF-. This phenotype is char-
acterized by the increased expression of ECM proteins
while maintaining expression of E-cadherin and has been
observed by others (3,31,32). NRK52E cells were infected
with CTGF containing adenovirus (Ad-CTGF) or treated
with recombinant human CTGF (rhCTGF) and the expres-
sion of ECM proteins was assessed at both mRNA and the
protein level (4). Interestingly, despite an increase in
-SMA and ECM proteins, these cells maintained a rela-
tively high level of E-cadherin mRNA (4). Because TGF-
B. WANG AND ASSOCIATES
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CTGF resulted in increased E-cadherin mRNA levels, we
wanted to know the effect of CTGF on miR-192/215. We
hypothesized that miR-192/215 would be increased in cells
expressing more E-cadherin as these cells would express
less ZEB2, the transcriptional repressor of E-cadherin. To
test this hypothesis, we obtained RNA from our well-
characterized study (4) and observed that miR-192 and
miR-215 were both signiﬁcantly elevated in cells infected
with Ad-CTGF or treated with rhCTGF (Fig. 5A and B).
These data were consistent with our other observations
that miR-192/215 regulate E-cadherin levels via ZEB2.
CTGF is thought to be downstream of TGF-, and both
factors are considered proﬁbrotic with overlapping func-
tions. Our data clearly demonstrate that CTGF and TGF-
both result in increased ECM production in proximal
tubular cells but also have distinct functions in that they
regulate miR-192/215 levels and, consequently, E-cadherin
in opposite directions.
DISCUSSION
In summary, we have demonstrated that TGF- regulates
the expression of some of the kidney-speciﬁc miRNAs in
renal cell lines. We clearly demonstrated that miR-192 and
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FIG. 4. Effect of miR-192/215 on E-cadherin expression in proximal
tubular cells. A: Proximal tubular cells were transfected with either
miR-control (miR-NC), miR-192, or miR-215 (100 nmol/l), and E-
cadherin expression was assessed by real-time quantitative PCR. Both
miR-192 and miR-215 resulted in an increase in E-cadherin mRNA, but
only the change with miR-215 was signiﬁcant (*P < 0.05, compared
with control). B: To test the effect of miR-192/215 in the context of
TGF-, NRK52E cells that were previously adapted to TGF- for >10
days were transfected with miR-control, miR-192, or miR-215, and
expression of E-cadherin was assessed by real-time quantitative PCR 3
days later. Both miR-192 and miR-215 signiﬁcantly increased E-cad-
herin mRNA (*P < 0.01, compared with control). C: Similar transfec-
tion experiments using miR-192 did not alter mRNA levels of ECM
genes or vimentin, compared with miR-control. D: Transfection with
miR-215 did not alter the expression of ECM genes or vimentin
compared with miR-control. E: NRK52E cells that had not been previ-
ously exposed to TGF- were transfected with miR-control, miR-192,
or miR-215, and 4 h later treated with TGF- (10 ng/ml). Cells were
harvested 3 days later, and expression of E-cadherin was assessed by
real-time quantitative PCR. TGF- treatment dramatically reduced
E-cadherin mRNA levels in cells transfected with miR-control (*P <
0.001, compared with no TGF- treatment). The reduction in E-
cadherin mRNA was partially but signiﬁcantly reversed by both miR-
192 and miR-215 (#P < 0.05, compared with miR-control with TGF-
treatment). All error bars represent  SEM.
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FIG. 5. CTGF increases miR-192/215 expression. A: NRK52E cells were
infected with Ad-CTGF or Ad-vector, and miR-192/215 levels were
assessed 6 days after infection (4). At this time point, ECM production
and E-cadherin RNA levels are increased as previously reported (4).
miR-192/215 levels were signiﬁcantly increased by CTGF (*P < 0.01
and *P < 0.05, respectively, compared with empty vector control). B:
NRK52E cells were treated with rhCTGF (250 ng/ml) for 6 days (4),
and miR-192/215 levels were assessed and were both found to be
signiﬁcantly increased (*P < 0.05) compared with control. C: Schema
showing the mechanism by which the proﬁbrotic factors TGF- and
CTGF regulate E-cadherin expression and ECM accumulation. How-
ever, they also regulate the expression of miR-192/215 in opposite
directions and, consequently, the expression of ZEB2, the transcrip-
tional regulator of E-cadherin, and E-cadherin. Error bars represent 
SEM.
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animals, and this decrease was associated with an in-
creased expression of ECM proteins. These results con-
ﬁrm that the diabetic milieu appears to alter miRNA
expression in the kidney, consistent with the effect of
TGF- in our in vitro experiments. We further demon-
strated that TGF- results in increased levels of ZEB2
mRNA and protein (Fig. 3B, D, and E), the transcriptional
repressor of E-cadherin, and consequently resulted in
decreased E-cadherin transcription in proximal tubular
cells. The mechanism is likely to involve miR-192/215,
which target to the 3UTR of ZEB2 to repress translation
of this gene (Fig. 3E). Importantly, we did not observe any
direct effect of miR-192/215 on the expression of collagens,
-SMA, vimentin, or ﬁbronectin in proximal tubular cells.
This ﬁnding is interesting because it suggests that the
miR-192/215 family, in contrast to the miR-200 family (7),
can regulate the expression of E-cadherin through ZEB2
independently of any changes in ECM protein expression.
Our ﬁndings in rat proximal tubular and mesangial cells
are in contrast with those previously reported (10) in
mouse mesangial cells. However cell culture conditions
were different in the experiments of Kato et al. (10), in
which serum-deprived conditions were used to establish a
baseline from which to measure the effect of TGF-. They
observed a 70% drop with serum deprivation, which was
essentially reversed by TGF-. They also observed very
little miR-215 in their mesangial cells. In our experiments,
under reduced serum conditions, TGF- resulted in de-
creased miR-192/215 levels, and our cells expressed both
miR-192 and miR-215. Kato et al. (10) also reported an
increase in miR-192 in diabetic kidney, in contrast to our
studies. The observed differences are likely to be due to
the different models and time points that were used. The
role and regulation of miR-192 may, in fact, be far more
complex, since Wang et al. (19,20) demonstrated increased
glomerular ﬁltration rate correlated with miR-192 levels in
IgA nephropathy but not in control patients or patients
with glomerulosclerosis in whom slightly decreased levels
were observed. They demonstrated a clear correlation
between the miR-200 family and markers of ﬁbrosis;
however, no correlation was found between markers of
EMT or ﬁbrosis with miR-192 levels, consistent with our
data. More recently, Krupa et al. (28) demonstrated de-
creased miR-192 expression in human diabetic kidney
samples. Our data are consistent with these recent studies
(19,20), but further demonstrate that miR-192/215 do not
directly affect the expression of ﬁbrotic markers and ECM
proteins.
In this work we have also demonstrated that both TGF-
and CTGF increase ECM expression independently of
E-cadherin. TGF- lowers E-cadherin, whereas CTGF,
which is a driver of the partial EMT phenotype, increases
E-cadherin expression (4). The mechanism by which these
factors control E-cadherin expression is likely to involve
miR-192/215, which regulate ZEB2 independently of ECM
protein expression as demonstrated in our experiments
(Fig. 4). Our experiments also suggest that the entire
“classic EMT” program, which is observed in vitro with the
associated decrease in E-cadherin expression, might not
be critical for the development and progression of renal
ﬁbrosis (Fig. 5C). Similar observations have been made
with the Id1 gene, which decreased E-cadherin expression
without altering the expression of ECM proteins (32).
Our work demonstrates a clear link between miRNA-
192/215 and ZEB2 in TGF-/CTGF-mediated changes in
E-cadherin expression. Furthermore, we demonstrate that
these changes can occur independently of matrix protein
synthesis, suggesting that the classical multistep EMT
program may not be necessary for ﬁbrogenesis to occur.
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